Business Description
Cyclerion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US23255M2044
Share Class Description:
CYCN: Ordinary SharesTotal Employee Number:
1Description
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.73 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -53.51 | |||||
Beneish M-Score | -5.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 68.3 | |||||
3-Year EBITDA Growth Rate | 43.1 | |||||
3-Year EPS without NRI Growth Rate | 43.4 | |||||
3-Year FCF Growth Rate | 61.8 | |||||
3-Year Book Growth Rate | -20.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.85 | |||||
9-Day RSI | 38.39 | |||||
14-Day RSI | 41.98 | |||||
3-1 Month Momentum % | 18.6 | |||||
6-1 Month Momentum % | 153.19 | |||||
12-1 Month Momentum % | 57.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.82 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.75 | |||||
Days Sales Outstanding | 105.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.6 | |||||
Shareholder Yield % | -5.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -359.16 | |||||
Net Margin % | -353 | |||||
EBITDA Margin % | -359.16 | |||||
FCF Margin % | -237.74 | |||||
OCF Margin % | -234.26 | |||||
ROE % | -85.83 | |||||
ROA % | -74.18 | |||||
ROIC % | -121.4 | |||||
3-Year ROIIC % | 1015.49 | |||||
ROC (Joel Greenblatt) % | -3245.66 | |||||
ROCE % | -87.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.33 | |||||
PB Ratio | 2.91 | |||||
Price-to-Tangible-Book | 2.91 | |||||
EV-to-EBIT | -2.14 | |||||
EV-to-EBITDA | -2.14 | |||||
EV-to-Revenue | 7.69 | |||||
EV-to-FCF | -3.24 | |||||
Earnings Yield (Greenblatt) % | -46.73 | |||||
FCF Yield % | -28.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CYCN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclerion Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.9 | ||
| EPS (TTM) ($) | -11.62 | ||
| Beta | 1.4903 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 122.27 | ||
| 14-Day RSI | 41.98 | ||
| 14-Day ATR ($) | 3.562571 | ||
| 20-Day SMA ($) | 28.090999 | ||
| 12-1 Month Momentum % | 57.96 | ||
| 52-Week Range ($) | 7.186199 - 59.359999 | ||
| Shares Outstanding (Mil) | 0.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclerion Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclerion Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 64 days | ||
| 0.142857:1 Stock Split | 2026-09-09 | 29.75 (-6.18%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 24.43 (+2.35%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 22.33 (+4.25%) | ||
| Cyclerion Therapeutics - Korsana Biosciences Merger Agreement Announcement Conference Call | 2026-04-01 08:00 | 10.85 (+5.80%) | ||
| Annual report for 2025 | 2026-03-31 | 10.11 (-0.34%) | ||
| Medsteer Collaboration Agreement and Business Update | 2026-01-06 08:00 | 9.66 (+2.99%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 9.94 (-2.74%) | ||
| Pioneering a New Era in Neuropsychiatric Therapies | 2025-09-24 10:30 | 21.14 (+6.71%) | ||
| Second quarter earnings results for 2025 | 2025-08-05 | 19.50 (+9.23%) |
Show
Entries
Cyclerion Therapeutics Inc Frequently Asked Questions
What is Cyclerion Therapeutics Inc(CYCN)'s stock price today?
The current price of CYCN is $23.94. The 52 week high of CYCN is $59.36 and 52 week low is $7.19.
When is next earnings date of Cyclerion Therapeutics Inc(CYCN)?
The next earnings date of Cyclerion Therapeutics Inc(CYCN) is 2026-11-13 Est..
Does Cyclerion Therapeutics Inc(CYCN) pay dividends? If so, how much?
Cyclerion Therapeutics Inc(CYCN) does not pay dividend.
Press Release
Articles on Cyclerion Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers